Objective

Compare COPD-related, non-COPD pneumonia-related, and all-cause health care resource utilization (HCRU) among initiators of tiotropium+olodaterol (TIO+OLO) – a fixed-dose dual bronchodilator approved in the United States (US) – vs. TT in an on-treatment study design.